Advantage Alpha Capital Partners LP Stoke Therapeutics, Inc. Transaction History
Advantage Alpha Capital Partners LP
- $337 Million
- Q2 2025
A detailed history of Advantage Alpha Capital Partners LP transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 17,888 shares of STOK stock, worth $443,980. This represents 0.06% of its overall portfolio holdings.
Number of Shares
17,888Holding current value
$443,980% of portfolio
0.06%Shares
1 transactions
Others Institutions Holding STOK
# of Institutions
139Shares Held
57.6MCall Options Held
2.7KPut Options Held
57.4K-
Black Rock Inc. New York, NY5.41MShares$134 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR5.4MShares$134 Million18.16% of portfolio
-
Rtw Investments, LP New York, NY5.12MShares$127 Million0.89% of portfolio
-
Baker Bros. Advisors LP New York, NY4.63MShares$115 Million0.53% of portfolio
-
Redmile Group, LLC San Francisco, CA4.38MShares$109 Million6.04% of portfolio
About Stoke Therapeutics, Inc.
- Ticker STOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,419,300
- Market Cap $978M
- Description
- Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...